<DOC>
	<DOC>NCT00135421</DOC>
	<brief_summary>The purpose of this clinical research study is to learn whether BMS-562086 is both safe and effective in treating outpatients with major depressive disorder.</brief_summary>
	<brief_title>Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Outpatient women meeting Diagnostic and Statistical Manual of Mental Disorders Manual, Fourth Edition, Text Revision (DSMIV TR) criteria for a single or recurrent, nonpsychotic episode of Major Depressive Disorder (296.2x and 296.3x). Patients whose current depressive episode is at least three months in duration at the Baseline Visit. Males Patients with treatment resistance to other antidepressants</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2008</verification_date>
</DOC>